Phase I trial of a sustained-exposure formulation of gacyclidine (OTO-311) as a potential therapy for tinnitus.

Trial Profile

Phase I trial of a sustained-exposure formulation of gacyclidine (OTO-311) as a potential therapy for tinnitus.

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Mar 2017

At a glance

  • Drugs Gacyclidine (Primary)
  • Indications Tinnitus
  • Focus Adverse reactions
  • Sponsors Otonomy
  • Most Recent Events

    • 02 Mar 2017 According to an Otonomy media release, status changed from recruiting to completed.
    • 03 Nov 2016 According to an Otonomy media release, several dose cohorts in the trial have been completed without patient tolerability concerns and the trial will remain open into 2017 pending the potential evaluation of additional dose levels in order to establish a maximum tolerated dose.
    • 16 Nov 2015 This trial is expected to be completed in the first half of 2016, according to an Otonomy media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top